Topamac
✅ Controls Seizure Disorders
✅ Prevents Migraine Headaches
✅ Manages Lennox-Gastaut Syndrome
✅ Reduces Nerve Pain
✅ Enhances Cognitive Functioning
Topamac contaoins Topiramate
✓ Medisch beoordeeld door Morgan Ellis — Apotheekonderzoeker · 8 jaar ervaring · Laatst beoordeeld: mei 2026
⚡ Quick Answer — Topamac — topiramate 25 mg / 50 mg, multi-indication anticonvulsant
Topamac is topiramate 25 mg / 50 mg, an anticonvulsant licensed for epilepsy and migraine prophylaxis and used off-label for alcohol use disorder, weight management, and binge-eating disorder. Slow titration (25 mg weekly increments) over 8 weeks limits cognitive side effects (“topa-dopa”). Renal-dose adjusted. Pregnancy risk — oral cleft malformation. Watch for kidney stones, glaucoma, metabolic acidosis.
📦 Elke bestelling is gedekt door onze Reshipment Assurance Policy — als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.
Waarom bestellen bij MedsBase
Onze generieke medicijnen zijn afkomstig van WHO-GMP gecertificeerde fabrikanten en worden wereldwijd verzonden in discrete, eenvoudige verpakkingen — geen medicijnnaam op de buitenkant van het pakket. Betalingen met kaart worden verwerkt via een gereguleerde processor (betalingsoverzichten vermelden een gereguleerde kaartbetalingprocessor — nooit “MedsBase” of een medicijnnaam). Crypto en SEPA bankoverschrijvingen worden ook geaccepteerd. Elke bestelling wordt ondersteund door ons Reshipment Assurance Policy.
What is Topamac?
Topamac is a multi-indication anticonvulsant containing topiramate 25 mg / 50 mg (film-coated tablets), supplied by Cipla. It is licensed in adults and children for partial-onset and generalised tonic-clonic seizures (monotherapy or adjunctive) and for migraine prophylaxis. Off-label evidence supports use in alcohol use disorder, binge-eating disorder, idiopathic intracranial hypertension, essential tremor, and bipolar disorder — though the strongest non-licensed evidence is for AUD (Johnson 2007).
How topiramate works
Topiramate has multiple, complementary CNS actions:
- Sodium-channel blockade — reduces neuronal excitability (anticonvulsant)
- GABA-A potentiation at a non-benzodiazepine site — increases inhibitory tone
- Glutamate AMPA / kainate receptor antagonism — reduces excitatory neurotransmission; thought to be the main mechanism for AUD effect
- Carbonic anhydrase inhibition — explains the metabolic acidosis, kidney-stone, and weight-loss side-effect profile
- Voltage-dependent calcium channel modulation
The combination of glutamate AMPA antagonism and GABA-A potentiation is thought to dampen the dopaminergic reward circuitry that drives alcohol craving and binge eating — the same pathway naltrexone targets through opioid receptors.
How Topamac is used
Slow titration is essential — rapid escalation produces unacceptable cognitive side effects (the “topa-dopa” phenomenon: word-finding difficulty, mental slowing, confusion). Standard 8-week titration:
| Week | Morning dose | Evening dose | Total daily |
|---|---|---|---|
| 1 | — | 25 mg | 25 mg |
| 2 | 25 mg | 25 mg | 50 mg |
| 3 | 25 mg | 50 mg | 75 mg |
| 4 | 50 mg | 50 mg | 100 mg |
| 5–8 | increase by 25 mg/week | increase by 25 mg/week | up to 200 mg/day |
| Maintenance | varies | varies | varies by indication (see below) |
| Indicatie | Target maintenance dose | Opmerkingen |
|---|---|---|
| Migraine prophylaxis | 50–100 mg/day in two divided doses | Often effective at 100 mg; higher doses raise side-effect rate without much extra benefit |
| Adult epilepsy (adjunctive) | 200–400 mg/day in two divided doses | Usual maintenance; some patients tolerate up to 1,600 mg/day |
| Alcohol use disorder (off-label) | Titrated to 200–300 mg/day | Off-label — Johnson 2007 trial used 300 mg target; lower doses (100–150 mg) sometimes effective with fewer cognitive side effects |
| Binge-eating disorder (off-label) | 200–400 mg/day | Off-label; FDA-licensed combination phentermine+topiramate exists for weight loss |
Take with or without food. Adequate hydration reduces kidney-stone risk substantially (aim for > 2 L water daily). Once the maintenance dose is reached, treatment is usually continued for at least 6–12 months for AUD, indefinitely for chronic seizure or migraine prophylaxis.
Renal-dose adjustment
| eGFR (mL/min/1.73 m²) | Adjustment |
|---|---|
| > 70 | Standaard |
| 30–70 | Reduce by 50%; titrate slower |
| < 30 | Reduce by 50%, monitor closely |
| Haemodialysis | Supplemental dose post-dialysis (significantly cleared) |
Side effects (slow titration is the key to tolerability)
- Cognitive slowing, word-finding difficulty (“topa-dopa”) — the dose-limiting side effect; reduces with slower titration and lower target dose
- Paraesthesia (tingling in fingers and lips) — very common, usually mild; reduced by potassium-rich diet
- Weight loss — consistent and substantial (mean ~5% body weight); usually welcome but may be problematic in low-BMI patients
- Nephrolithiasis (kidney stones) — ~1.5% risk; carbonic anhydrase inhibition raises urine pH and lowers citrate. Risk reduced by adequate hydration; avoid in patients with stone history if other options exist
- Acute angle-closure glaucoma — rare but ophthalmic emergency, usually within first month; eye pain, blurred vision, red eye = stop drug and seek immediate ophthalmology assessment
- Metabolic acidosis (low bicarbonate) — mild and asymptomatic in most; check baseline + periodic bicarbonate
- Oligohidrosis and hyperthermia — reduced sweating, mainly in children; caution in hot climates
- Mood disturbance, depression, suicidal ideation — class signal across anticonvulsants; monitor
- Anorexia, taste perversion (carbonated drinks taste flat — classic and reversible)
Geneesmiddelinteracties
| Geneesmiddel / klasse | Effect | Action |
|---|---|---|
| Oral contraceptives (combined) | Reduced efficacy at > 200 mg/day topiramate | Use higher-oestrogen pill, IUD, or barrier |
| Carbamazepine | Lowers topiramate level (CYP3A4 induction) | May need higher topiramate dose |
| Fenytoïne | Lowers topiramate level; raises phenytoin level slightly | Monitor levels |
| Other carbonic anhydrase inhibitors (acetazolamide, zonisamide, dichlorphenamide) | Stacked metabolic acidosis and stone risk | Avoid combination |
| Lithium | Variable lithium-level changes | Monitor lithium more frequently after dose change |
| Valproate | Both can cause hyperammonaemic encephalopathy | Caution; check ammonia if confusion develops |
| Alcohol | Cognitive impairment additive; alcohol increases topiramate effect on driving | Counsel patient |
| Metformine | Both raise lactate; theoretical lactic-acidosis stacking | Monitor; usually safe |
| Hydrochlorothiazide | Raises topiramate level | Monitor for side effects |
Contraindications and special populations
- Hypersensitivity to topiramate
- Recent acute angle-closure glaucoma episode (history of)
- Severe metabolic acidosis
- Pregnancy planning: avoid; switch before conception (see red box)
- History of nephrolithiasis — relative contraindication; weigh benefit and ensure aggressive hydration
- Children < 2 years (epilepsy use): specialist supervision only
Opslag
Store at room temperature (15–30 °C / 59–86 °F), in the original blister, away from direct light and moisture. Keep out of reach of children.
Veelgestelde vragen
Is topiramate licensed for alcohol use disorder?
No — it is used . De door de FDA goedgekeurde medicijnen voor vrouwelijke hypoactieve seksuele verlangensstoornis (HSDD) en vrouwelijke seksuele opwindingsstoornis (FSAD) zijn for AUD. The strongest evidence is the Johnson 2007 trial showing benefit at 300 mg/day across multiple AUD endpoints, replicated in COMBINE-style designs. The NIAAA acknowledges topiramate as an off-label option, particularly in patients who have not responded to naltrexone or acamprosate or who have comorbid migraine.
Why does titration have to be so slow?
Cognitive side effects (“topa-dopa”) emerge sharply at higher daily doses unless the brain has time to adapt. Titrating 25 mg per week over 8 weeks lets most patients reach a 100–200 mg target without significant word-finding difficulty. Faster titration is the most common reason for premature discontinuation.
Will I lose weight on it?
Almost certainly — topiramate produces a mean ~5% body-weight reduction over 6 months, mostly through reduced appetite and possibly altered taste. This is welcome in most AUD patients (alcohol calories add up), and is the basis for the FDA-licensed phentermine+topiramate weight-loss combination (Qsymia). Low-BMI patients may need monitoring.
Can I drink alcohol while on it?
Topiramate does not produce a disulfiram-like reaction. It does, however, additively impair cognition and driving, and the goal in AUD use is abstinence or reduction. Counsel patients to avoid alcohol where possible during the active titration period at minimum.
What about the kidney stone risk?
Topiramate raises urine pH and lowers urinary citrate via carbonic anhydrase inhibition, predisposing to calcium phosphate stones in roughly 1.5% of long-term users. Aggressive hydration (> 2 L water daily) substantially reduces risk. Patients with personal or strong family stone history should be counselled and monitored, and a different agent considered if stones occur.
What is the glaucoma warning?
A rare (< 0.1%) idiosyncratic acute angle-closure glaucoma can occur within the first month of starting topiramate, particularly in patients with shallow anterior chamber. Symptoms: severe eye pain, blurred vision, red eye, halos around lights. Stop the drug immediately and seek same-day ophthalmology review — permanent visual loss is possible without prompt treatment.
Why do carbonated drinks taste flat?
Carbonic anhydrase inhibition affects the salivary enzyme that helps you perceive carbonation. The flatness reverses on stopping. It is not a sign of toxicity but is one of the most distinctive topiramate experiences.
Can I take it with naltrexone or acamprosate?
Yes — combination is sometimes used in AUD when monotherapy has failed, with reasonable evidence and no major interaction. Adverse-event load rises slightly, mainly cognitive.
Is it safe in pregnancy?
No — topiramate is associated with a 2–3-fold increase in cleft lip/palate when used in the first trimester. Plan effective contraception and switch to lamotrigine or levetiracetam before conception if pregnancy is planned. Discuss with the prescriber as soon as pregnancy is suspected.
How long until I notice an effect?
Migraine and AUD effects emerge during titration but are clearest at the 100–200 mg maintenance dose, typically by week 8–12. If there is no benefit at 12 weeks of stable maintenance dose, the prescriber may stop or switch.
Gerelateerde alternatieven
Andere producten in Algemene gezondheid die klanten ook bekijken:
More options in Alcohol and Drug Treatment
Gerangschikt op recente bestelvolumes van MedsBase — wat andere klanten in deze categorie kiezen.
| Sterkte | 25 mg, 50 mg, 100 mg |
|---|---|
| Hoeveelheid | 30 Tablet/s, 60 Tablet/s, 90 Tablet/s, 120 Tablet/s |
| Farmaceutische vorm | Tablet/s |
| Fabrikant | Johnson & Johnson |
| Behandeling | Epilepsy/Seizures, Preventive treatment of migraine |
| Generiek merk | Topiramate |
Topamac
Vragen & antwoorden
Topamac
Gerelateerde producten
Beoordelingen
Er zijn nog geen beoordelingen